Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by NewAmsterdam Pharma N.V. NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September August 30, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results August 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia July 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 July 26, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors July 18, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers APGE ENGN NAMS NAMSW NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors July 08, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office June 11, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June May 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings May 21, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 09, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 May 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Tickers NAMS NAMSW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.